Neuroimaging biomarker sheds light on link between brain age, mortality risk | Pancreatic cancer guideline includes palliative care | Study: Biking to work reduces cardiovascular, cancer risks
April 27, 2017
CONNECT WITH SNMMI LinkedInFacebookTwitterYoutube
SNMMI SmartBrief
News for nuclear medicine and molecular imaging professionals
SIGN UP ⋅   FORWARD
Top Story
Neuroimaging biomarker sheds light on link between brain age, mortality risk
Researchers from the UK and Australia found that a brain-aging biomarker based on neuroimaging data showed that brains that appeared older were linked to increased mortality risk, poorer lung function, slower walking speed, reduced grip strength, lower fluid intelligence and higher allostatic load, and mortality risk prediction was improved by combining the biomarker and DNA-methylation-predicted age. The findings in Molecular Psychiatry suggest the biomarker could be useful in identifying asymptomatic people with adverse aging, researchers said.
HealthImaging.com (4/26) 
LinkedIn Twitter Facebook Google+ Email
Clinical News & Research
Pancreatic cancer guideline includes palliative care
An American Society of Clinical Oncology clinical guideline governing treatment of patients with metastatic pancreatic cancer includes strong recommendations that patients be informed about palliative care. The guideline, published in Journal of Oncology Practice following a review of scientific evidence, said patients will need assessments of symptom burden and, in most cases, those assessments will "indicate a need for formal palliative care consult and services."
ClinicalAdvisor.com (4/25) 
LinkedIn Twitter Facebook Google+ Email
Study: Biking to work reduces cardiovascular, cancer risks
A study published in The BMJ found riding a bike to work, compared with a sedentary commute, was associated with a 46% reduced risk of cardiovascular disease, a 45% lower likelihood of cancer and a 41% lower chance of premature death over five years. Researchers said walking to work was linked to a 27% lower risk of CVD and a 36% lower likelihood of dying from it.
Physician's Briefing/HealthDay News (4/24) 
LinkedIn Twitter Facebook Google+ Email
Industry Report
AnGes' IND for back pain drug approved by FDA
The FDA has approved the investigational new drug application filed by AnGes for its clinical trial of F-kappaB decoy oligo DNA as a treatment for discogenic lower back pain.
Reuters (4/24) 
LinkedIn Twitter Facebook Google+ Email
Adamas reports efficacy of ADS-5102 in Parkinson's disease
Pooled results from two late-stage trials of Adamas Pharmaceuticals' ADS-5102, or amantadine, showed that the drug produced a statistically significant reduction in "off time" and a significant reduction in dyskinesia associated with levodopa in patients with Parkinson's disease.
Seeking Alpha (free registration) (4/24) 
LinkedIn Twitter Facebook Google+ Email
News from the Field
Doctor: Patients should be active participants in their care
People who are active participants in their health care decisions, regardless of how bad their diagnosis, have the best chance of receiving care consistent with their values, goals and preferences, said palliative care specialist Dr. Steven Pantilat of the University of California at San Francisco School of Medicine. Pantilat, author of "Life After the Diagnosis," said patients should ask their physicians lots of questions and push for a prognosis.
The Sacramento Bee (Calif.) (tiered subscription model) (4/24) 
LinkedIn Twitter Facebook Google+ Email
Health Policy
FDA issues 14 warning letters, 4 online advisories over unapproved cancer drugs
Four online advisory letters and 14 warning letters were issued by the FDA to US-based firms for marketing and selling more than 65 products with claims that they could cure, prevent or reverse cancer, although the claims are not proven and the products have not gotten the approval of the FDA. The agency gave the companies 15 days to respond with plans on how they will address their violations, and companies that do not comply face product seizure and criminal prosecution that could result in a year in federal prison and a fine of either $100,000 or twice the company's gain on the fraudulent products.
Pharmacy Times online (4/25),  Regulatory Focus (4/25) 
LinkedIn Twitter Facebook Google+ Email
CMS sets deadline for comments on proposed EHR incentive program changes
The CMS will accept formal comments on proposed changes to the Medicare and Medicaid EHR Incentive Programs until June 13. These changes include revising the EHR reporting period from the full calendar year to any continuous 90-day period, implementing a policy that would not allow payment adjustments for eligible providers who conduct most of their professional services in ambulatory surgery centers, and adding a Medicare payment adjustment for eligible hospitals and professionals who cannot comply with meaningful-use requirements because of decertified technology.
BeckersHospitalReview.com (4/24) 
LinkedIn Twitter Facebook Google+ Email
Advancing Health Care
Survey examines instances of EHR outages affecting patient safety
EHRs
(Christopher Furlong/Getty Images)
SERMO surveyed 3,086 physicians from 26 countries and found that 46% have witnessed an EMR/EHR outage or malfunction that endangered a patient's health or safety. Fifty-five percent of physicians in the US said they experienced such an incident, followed by 46% -- the global average -- in Canada and the UK and 39% in France.
BeckersHospitalReview.com (4/24) 
LinkedIn Twitter Facebook Google+ Email
 
From SNMMI
Throwback Thursday: Save 30% on SNMMI's online reviews
For today only, we're turning back the clock and offering you 30% savings on the popular online reviews The Nuclear Medicine Review Course and the PET Online Review Workshop! No coupons needed. This week's Throwback Thursday deals end at 11:59 p.m. ET on April 27.
LinkedIn Twitter Facebook Google+ Email
Nuclear medicine technologists: Save money on these great study and reference tools
Save 10% on the Steves' Review of Nuclear Medicine Technology, 4th edition, and Practical Mathematics in Nuclear Medicine Technology, 2nd edition, when you purchase them together as part of the best-selling Technologist Study Combo. It's an in-depth review at a great price!
LinkedIn Twitter Facebook Google+ Email
Learn more about SNMMI:
SNMMI | News & Publications | Meetings | Education
Membership | Support Education/Research in Your Field
  
  
The empires of the future are the empires of the mind.
Winston Churchill,
statesman and prime minister
LinkedIn Twitter Facebook Google+ Email
  
  
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Christopher Black
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information